STM JOURNALS

International Journal of
Brain Sciences

ISSN: 3048-7935
Volume 2, Issue 2, 2025
July–December
DOI (Journal): 10.37591/IJBS

https://journals.stmjournals.com/ijbs

Review IJBS

Neuroimaging in Clinical Trials for Huntington's Disease: Emerging Research Findings – The Advancement in Directions and Implications

Vinod B. Bhamare[1], Sandip S. Patil[2,*]

Abstract

Neuroimaging is very important in coordinating and conducting Huntington's disease clinical trials as a tool in selecting patients, managing safety concerns, and assessing the benefits of interventions. This review presents the current uses and potential future uses of structural and functional magnetic resonance imaging (MRI), diffusion imaging, positron emission tomography (PET), proton magnetic resonance spectroscopy (MRS), perfusion imaging, and magneto encephalography (MEG) in HD trials. We describe how these modalities contribute to patient selection, biomarker optimization, and pharmacokinetic studies, as well as documenting disease amelioration and neuroplastic changes after treatment. Furthermore, they explore the difficulties of adapting neuroimaging approaches from research to clinical settings in relation to technical standardization, patient burden, costs for equipment, and difficulties of data interpretation. By critiquing, we identify novel developments in neuroimaging methods and discuss ways to enhance their application in HD trials. The review closes by highlighting the role of neuroimaging, in general, to improve patient prognosis and boost research in HD therapeutic interventions if implemented with precise modalities and research study designs. Huntington's disease (HD), Neuroimaging/clinical research, Drug trials, Magnetic resonance imaging (MRI), Positron emission tomography (PET), Magnetoencephalography (MEG), Patient subgrouping/characterization, Disease prevention and brain reorganization.

Keywords: Huntington's Disease (HD), neuroimaging, clinical trials, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Magnetoencephalography (MEG), patient stratification, disease modification, brain reorganization

INTRODUCTION

Huntington's disease abbreviated as HD is a typical autosomal dominantly inherited neurodegeneration disease characterized by an abnormality in the first exon of the HTT gene in which CAG triplet repeat is abnormally elongated to produce a mutant huntingtin protein. Commonly developing in middle age or later, HD always advances in its course of 15 to 20 years leading to severe neurological and functional impairments. The clinical presentation involves a triad of symptoms: neuropsychiatric abnormalities, memory and executive dysfunction, and gradual development of movement abnormalities. Symptoms during early stages may include behavioral and psychological changes, chorea and involuntary movements, and cognitive decline. Currently, the disease progresses and affects mobility, causing the patient to become almost entirely paralyzed and then die. Research in this area

***Author for Correspondence**
Sandip S. Patil
E-mail: sspatiljalgaon@gmail.com

[1]Research Scholar, Department of Computer Engineering, S.S.B.T. College of Engineering & Technology, Bambhori, Jalgaon, Maharashtra, India.
[2]Associate Professor, Department of Computer Engineering, S.S.B.T. College of Engineering & Technology, Bambhori, Jalgaon, Maharashtra, India.

Received Date: April 04, 2025
Accepted Date: May 22, 2025
Published Date: May 26, 2025

Citation: Vinod B. Bhamare, Sandip S. Patil. Neuroimaging in Clinical Trials for Huntington's Disease: Emerging Research Findings – The Advancement in Directions and Implications. International Journal of Brain Sciences. 2025; 2(2): 1–13p.

is still ongoing with no completely ideal disease-modifying drugs developed which still calls for better improved clinical methods including the imaging of the brain in the HD population. There are currently several putative disease modifying therapies for HD under development that predominantly target reduction of the load of the main neurotoxic product, the mHTT protein. Such treatment strategies can include prevention of the generation of more mHTT, enhancing HTT clearance to prevent accrued damage, and manipulation of DNA repair pathway to counter somatic mutational burden which leads to the manifestation of the disease. Further strategies aim to directly target other secondary path physiological processes in the hope of modifying the disease course. At present, there are numerous ongoing phase II and III clinical trials, which suggest the severe and urgent necessity of effective treatment in HD. Nonetheless, as the nature of HD pathology is complex, it is important to design clinical trials to obtain reliable data. Neuroimaging is a valuable tool in reducing the time involved in several aspects of clinical trials, such as participant identification, safety assessments, pharmacodynamics investigations, and estimates of disease-modifying effects. Considering the changes in HD research, this review presents a modern-day outlook of neuroimaging to enable the performance of more effective and accurate clinical trials particularly with techniques and practicality in mind. HD is a rare autosomal dominant neurodegenerative disorder that progressively destroys nerve cells and results in several physiological and psychological impairments. The many subtypes of HD based on age of onset and rate of progression also create other issues for clinical research and especially how patients are characterized. Thus, understanding these categories and their clinical course is critical to personalizing treatments, and improving trial design.

TYPES OF HUNTINGTON'S DISEASE

Adult-Onset Huntington's Disease

The commonest type that usually presents symptoms at ages between thirty and fifty years. Characterized by slow onset of chorea, initial signs of dementia and psychosis. He loses ground steadily and in a period of fifteen to twenty years he is substantially incapacitated. Most of the clinical trials for this condition focus on slowing the progress of the disease and preserving functional outcomes for as long as possible [1].

Early-Onset Huntington's Disease

It is presented in individuals who are below the age of 30 years and is a less common but more virulent form. Faster progression along with elevated rates of such psychological disturbances as temper tantrums, sad moods, and worse motor control. Requires individualized interventions because it progresses relatively quickly and results in early functional decline.

Juvenile Huntington's Disease (JHD)

Rare and severely affected youngsters, often progressing within ten years after onset. They normally include seizures, slowness of movements, and a significant decrement in cognitive function. The feasibility of the JHD studies is limited by restricted access to patients compared to health controls and ethical issues concerning the population under study.

Late-Onset Huntington's Disease

It develops after 60 years of age but has less severe symptoms and progresses slowly. In most cases, patients will exhibit a decline in psychiatric symptoms and chorea though the cognition may be worsened in a more complex manner. The research within these variants focus on the patients' quality of life and functional status because the progression of the disease is relatively slower. Variant Forms of Huntington's Disease HD arises from a CAG repeat in the HTT gene; however, there are other genetic disorders causing similar phenomenology that could complicate diagnosis and patient enrolment for trials:

Huntington's Disease-Like 2 (HDL2)

A rare inherited disorder of genetic dominant type with clinical features like Huntington's chorea: reversible involuntary movements and dementia. Causal to genetic mutations in the JPH3 gene. The distinction between HDL2 and HD is of great importance for the proper identification and enrolment of the participants in the clinical trials.

Spinocerebellar Ataxia Type 17 (SCA17)

Another dominance total mutant disease is the syndrome is presenting symptoms resembling Huntington's disease – chorea, dementia, and psychological disorders. Consequent from an atypical expansion – in the TBP gene. Neuroimaging may be useful in differentiating between SCA17 and HD during the recruitment of patients for experimental studies.

DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY (DRPLA)

An orphan disease with manifestations of chorea, myoclonus, dementia, seizures: imitation of juvenile and early-onset Huntington's disease. Consequent to DNA alterations in the gene locus at ATN1. Low specificity poses a significant problem of classification in studies involving children, hence the need for precise diagnosis. Clinical Relevance of Subtypes and Variants in Neuroimaging and Trials: Understanding the various subtypes and variation forms of HD is important in properly and effectively conducting clinical research. Structural MRI enables the different classifications of HD in addition to the use of PET scans for observing illness progression across various subtypes. For instance:

In this case, structural MRI can differentiate atrophy profiles that depend on the age of onset and the degree of severity of Huntington's disease (HD).

The so-called diffusion MRI can facilitate the determination of white matter integrity to assess the progression of the disease more accurately in the case of juvenile Huntington's disease.

MRI and PET help determine unique biomarkers of phenotypes, like HDL2 and SCA17, ensuring scientists recruit proper participants for the study.

By comprehending these disparities, researchers may devise more precise treatments and utilize neuroimaging biomarkers to evaluate the effectiveness of therapy more efficiently. This customized strategy is particularly essential due to the diverse course and symptomatology of HD and its associated illnesses [2].

Structural/Volumetric MRI

Structural magnetic resonance imaging (sMRI) is a non-invasive method for viewing cerebral anatomy and characterizing its macrostructure, characterized by high spatial resolution. Although it is customary to acquire 3D T1-weighted images at a 1 × 1 × 1 mm isotropic resolution (ideally at 3 Tesla), even higher resolutions are feasible but seldom employed in clinical studies. T1-weight MRI scans are widely used in MS and other neurodegenerative disorders, for example in Huntington's disease (HD) given their ability for determination of brain tissue volumes. These scans afford excellent contrast between gray and white matter as well as CSF; therefore, they are critically important to assess structural changes that are pertinent to disease processes. The quantification method involves determination of volume of gray matter, white matter and CSF at the initial time then follow up over time by serial scans. These modifications, particularly cerebral atrophy – serve as markers of disease progression in these volumes [3].

Diffusion MRI (dMRI)

dMRI is an advanced MRI technique that measures the diffusion of water in the tissue with special reference to white matter in the human brain. In healthy tissue, the water molecules are known to travel along the axonal channels and reveal structural and connection data. In other neurological disorders, for instance Huntington disease (HD), dMRI helps the identification of changes in the white matter before the gross atrophy of gray matter. Specifically, diffusion MRI is a very valuable tool in early diagnosis of a disease, its progression follow-up, and evaluation of response to therapeutic interventions in clinical trials research. Primary dMRI strategies include Diffusion Tensor Imaging (DTI), Mean Diffusivity (MD), Fractional Anisotropy (FA), and Tract-Based Spatial Statistics (TBSS), each presenting different views on cerebral changes in Huntington's Disease HD Analyses of diffusion-weighted imaging (DWI) data utilizing diffusion tensor imaging (DTI) typically yield the following metrics: fractional anisotropy (FA), which quantifies diffusion directionality; mean diffusivity (MD); axial diffusivity (AD), measured along the principal fiber direction; and radial diffusivity (RD), assessed perpendicular to the principal fiber direction (refer to the review by Estevez-Fraga et al. [4]). A decline in structural integrity is often indicated by a reduction in FA and AD, accompanied by an elevation in RD and MD. DTI measures are influenced not only by biological processes (such as myelin, axon membrane, and density) but also by the geometrical characteristics of the fibers (such as fiber crossing or kissing, which may result in a decrease in FA), complicating their interpretation regarding specific biological properties of white matter [5]. Recent advancements have led to the development of more complex models to analyze "multi-shell" DWI data collected across various b-values, enabling distinct estimate of extracellular diffusivity at lower b-values and intracellular diffusivity at higher b-values. For example, neurite orientation dispersion and density imaging (NODDI) and the composite hindered and restricted model of diffusion (CHARMED) yield indices of intracellular diffusion signals that estimate axon density and demonstrate sensitivity to white-matter neuropathology in Huntington disease. Alongside the selection of DWI acquisition and model for metric generation, various preprocessing techniques must be evaluated (e.g., correction for eddy currents, motion, and geometric distortion). Additionally, a range of imaging tools for analysis is available, including region-specific or white matter tract assessments, whole-brain methodologies, such as voxelwise tract-based spatial statistics (TBSS) [6], tractography, and graph theory (Table 1). Considering that numerous analytical techniques are presently most appropriate for exploratory analyses in clinical trials, we advocate for the priori selection of a method, accompanied by a clear specification of statistical thresholds and the inferences to be derived, elucidating the rationale for that selection before initiating statistical data analysis.

LITERATURE SURVEY

In literature review of scholarly articles, one focuses on identifying and integrating research studies regarding the subject matter. This is a literature survey based on the previously submitted abstract on neuroimaging in clinical trials for Huntington's disease (HD). It highlights major findings or patterns and gaps in knowledge from prior studies.

Role of Neuroimaging in HD Trials: Neuroimaging has become an essential instrument in clinical trials for Huntington's disease (HD), assisting researchers in several facets of trial design and implementation. It facilitates the early identification of structural and functional alterations in the brain, frequently prior to the manifestation of clinical symptoms. The early identification facilitates participant selection by enrolling patients at the suitable stage of illness progression, hence augmenting this sensitivity to treatment benefits. Furthermore, neuroimaging offers an objective method to assess safety, detecting any detrimental impacts on cerebral [7].

Structure and function result from experimental therapies. Researchers can quantify disease progression and examine therapy effects over time using modalities, such as structural MRI (which measures brain shrinkage), functional MRI (which evaluates changes in brain activity), and PET

imaging (which monitors molecular changes, such as neuroinflammation). Neuroimaging is especially significant in illustrating disease transformation, as it enables accurate Quantification of minor biological alterations that correspond with enhancements in clinical outcomes. These characteristics render it essential for the development and validation of innovative medicines, guaranteeing that studies are scientifically rigorous and yield significant findings [8].

Table 1. Types of MRI techniques.

MRI Modality	Purpose in HD Research and Trials	Advantages	Limitations
Structural MRI	Measures brain atrophy (e.g., caudate, putamen). Tracks change in gray and white matter volume.	High spatial resolution. Detects brain volume loss over time.	Cannot directly assess functional changes. Limited sensitivity in early stages.
Functional MRI (fMRI)	Evaluates brain activity during cognitive or motor tasks. Identifies functional reorganization in response to therapies.	Non-invasive. Detects task-specific brain activation.	Susceptible to motion artifacts. Requires patient compliance.
Diffusion MRI (dMRI)	Assesses white matter integrity and connectivity. Useful for tracking macrostructural damage over time.	Sensitive to white matter degeneration. Provides insights into neural pathways affected by HD.	Interpretation can be complex. Affected by noise and motion artefacts.
Diffusion Tensor Imaging (DTI)	A specific type of dMRI that measures fractional anisotropy (FA) to assess white matter tracts.	Quantifies white matter disruption. Can track disease progression in early stages.	May not detect subtle changes in complex regions. Requires advanced post-processing.
Magnetic Resonance Spectroscopy (MRS)	Measures neurochemical changes (e.g., N-acetylaspartate, glutamate). Evaluates metabolic dysfunction in HD.	Provides insights into cellular metabolism. Non-invasive method for biochemical analysis.	Limited spatial resolution. Requires expertise in interpretation.
Perfusion MRI (Arterial Spin Labeling – ASL)	Assesses cerebral blood flow (CBF). Helps detect vascular changes related to disease progression.	Non-invasive measurement of blood flow. Useful in detecting early functional impairments.	Lower spatial resolution compared to other MRI modalities. Sensitive to noise.

Diffusion MRI (dMRI) and White Matter Integrity

Diffusion Magnetic Resonance Imaging (dMRI) is a current neuroimaging technique used for evaluating microstructural changes in white matter that are implicated in the pathophysiology of neurological diseases including Huntington's disease. One of the most common quantitative dMRI approaches is called Diffusion Tensor Imaging (DTI), which measures the anisotropic water diffusion through the white matter tracts in terms of Microscopic Fractional Anisotropy (FA) and Mean Diffusivity (MD). It is proven in HD that there is the reduction of FA and increase in MD showing axonal deteriorative changes, demyelination and impaired interaction between the white matter tracts involving most prominently the connection between the cortex and the striatum (Estevez-Fraga et al., 2020). Such alterations occur often before the signs of the clinical disease, making dMRI a valuable tool for early diagnosis and tracking the progression of the disease. As for the models, NODDI and CHARMED help to gain even more details as they differ intracellular and extracellular water diffusion, estimate neuronal density, and describe features of white matter damage. They improve appreciation of fine gradations that standard DTI could miss, helping investigators grasp the cellular evolution of HD more accurately. dMRI strategies reveal microstructural changes and provide quantitative markers for tracking the therapeutic outcome in therapeutic trials which promote identifying disease-modifying therapies [9].

Functional MRI (fMRI) for Network Analysis

Functional MRI (fMRI) is readily utilized to study brain activity because it measures changes in blood flow most substantially by means of BOLD signals. It enables the assessment of the effects on the various networks and, therefore, primary information regarding the functional abnormalities associated with HD is generated. Research shows that HD has a significant impact on the small important networks, such as DMN which is active during rest and is spared in other conditions and deals with the thoughts about oneself, memory and emotions. Based on the results obtained in the present study regarding the disrupted DMN connectivity in HD patients and primate models, future deterioration of cognition and mental symptoms commonly seen in this disorder may be expected. Research involving resting state fMRI have shown that the dynamics in the cortico-striatal network for the executive functions and motor coordination is impaired. More importantly, such changes in connectivity may be observed in non-clinical symptomatic but asymptomatic HD gene carriers [10], suggesting that neuropathological malfunction may precede clinical dysfunction. This early discovery indicates that fMRI might be a useful biomarker in charting the course of illness progression. In addition, task-based fMRI studies have shown changed activation in the motor cortex and basal ganglia which are critical for handling voluntary movements. These changes in brain metabolism correlate with the motor dysfunctions characteristic of Huntington's disease, such as chorea – irregular, uncontrolled movements and bradykinesia – slow movements. In motor activities, while anticipating activation in these areas, fMRI shows that one might find that activation is either dampened or altered – a sign of the neurodegenerative process. Due to the scope that is available for investigation in fMRI, our understanding of the disruption in brain function in HD is improved and, therefore, the effects on cognitive and motor networks. This knowledge can direct clinical practice by identifying possible interventional candidates and consider the efficacy of emerging anti-disease/alleviating treatments [4].

Positron Emission Tomography (PET) and Molecular Imaging

Structural imaging also notes that PET has the potential to evaluate molecular variation including neuroinflammation and receptor available bindings. Dopamine receptor PET has been used in other studies which reduce dopamine signaling in the striatum which is in line with motor complications found in HD. In addition, PET imaging has been employed to assess microglial activation that may have implications to the understanding of neuroinflammation in HD (Sturrock et al., 2015). Of these parameters, PET imaging is especially valuable for tracking pharmacodynamics and target engagement of experimental treatments [11].

Magnetic Resonance Spectroscopy (MRS) for Metabolite Analysis

MRS reveals biochemical characteristics of the brain by revealing metabolite content of the tissues, such as N-acetylaspartate (NAA) and Glutamate. Reduced NAA signal correlates with neuronal volume loss and impaired cellular metabolism that is characteristic of HD. Converging evidence from HD patients has implicated changes in glutamate and myo-inositol contents that may require treatments based on neuroprotection (Cozzi et al., 2020) [12].

Challenges in Translating Neuroimaging to Clinical Trials

Despite the potential of neuroimaging, several challenges remain in translating research methodologies into clinical trials: Standardization of protocols: Source: Several factors related to MRI cause heterogeneity and reduce the likelihood of replicating findings across sites.

Patient burden: Prolonged scanning also poses difficulties for HD patients and particularly those with severe motor manifestation (Figure 1).



Figure 1. Neuro image scan.

Interpretation complexity: NODDI is an example of a highly developed technique, the analysis of which can be carried out only with the help of additional specialized software, which may hinder its active use in general clinical trials [13].

Trends and Future Directions in Neuroimaging for HD Trials

Modern developments indicate that the new focus can be made on multimodal imaging strategies that involve structural, functional, and molecular imaging in the investigation of the phenotype in HD. Future directions include

- *Longitudinal Studies:* To get a clearer picture of how diseases advance and whether treatments are effective.
- *Artificial Intelligence and Machine Learning:* To increase the efficiency of automated photo analysis and for predictive analytics.
- *Multi-Center Collaborations:* Regarding standardization problems and data exchange.

METHODOLOGY

Neuroimaging to Aid Participant Selection, Enrichment, Stratification and Safety Monitoring

To review how the different neuroimaging methods, such as Structural MRI sMRI, Diffusion MRI (dMRI) functional MRI (fMRI), Magnetic Resonance Spectroscopy (MRS), Positron Emission Tomography (PET) and Magnetoencephalography (MEG) assist in participant selection, enrichment, stratification and safety monitoring in Huntington's disease HD clinical trials, we can look at each neuroimaging method

Participant Selection

Neuroimaging is central for sample exclusion/inclusion criteria, like early manifestations of HD pathology, which translates into rigorously quantifiable therapeutic responses.

- *Structural MRI:* Originally employed for the assessment of striatal atrophy in HD, T1-weighted structural MRI enables investigators to recruit individuals with disease progression. For instance, only those who exhibit definite signs of caudate or putamen degeneration will be enrolled in early intervention trials [14].
- *Diffusion MRI (dMRI):* In this way, dMRI using FA determines patients with tract alterations in cortico-striatal connections. Among them are those who present the early losses of connectivity, thus being useful for pointing out those who may have further progression.
- *PET:* Dopamine receptor availability is indicated by PET imaging as being lower, which is useful for the inclusion based on motor manifestations. Any candidate who is already exhibiting early motor deficits might benefit from striatal dopamine dysregulation reduction.
- *MEG:* While not commonly applied to the participant selection process, the optical MEG technique provides information on neuronal oscillations, which may allow indications of early neurofunctional disturbances directing the choice of participants [13].

Enrichment

Enrichment is the process of choosing those males that will transform and display measurable illness progression hence improving trial efficacy as well as reducing variance.

Structural MRI

Measuring the volume and density of gray and white matter requires high image contrast to define participants progressing at a specific rate, thus improving trials containing those anticipated to exhibit credible clinical change. It is documented that patients who have an early atrophy of the caudate nucleus, which can be detected by structural MRI, may develop the disease.

Diffusion MRI

Common findings in diffusion MRI of subjects with Huntington disease include reduced fractional anisotropy (FA) and increased mean diffusivity (MD) implying axon loss and deteriorating white matter. Having people with such indicators can improve trials by focusing more on subjects with a faster decline.

Functional MRI (fMRI)

With resting-state fMRI, the investigators identify participants demonstrating reduced cortico-striatal connectivity, so including more participants with early-stage changes in the networks. He contends that it is such people that are likely to demonstrate changes in response to treatment regimens. Magnetic Resonance Spectroscopy (MRS) provides biological markers through the measurement of concentrations of neurotransmitters in the brain, such as glutamate and GABA. Including patients with altered neurotransmitters in a study might help predict the metabolic alterations characteristic to a disease's progression [15].

Stratification

To needs-based segregation offers a breakdown of populations into subgroups based on imaging biomarkers that can easily help the researchers analyze response variations according to the illness profiles.

- *Structural MRI:* The participants can be divided with reference to the amount of damage in gray matter of several areas, such as the cortex region and the basic ganglia region. This classification helps in subjecting the samples into subclasses because, in every class, related levels of atrophy are reviewed; this helps in increasing the reliability of the results of the study.
- *Diffusion MRI:* dMRI may group subjects based on differences in white matter microstructure, as reflected by differences in FA of the various pathways. Lower FA values are often associated with higher degrees of white matter deterioration and, therefore, subjects with these characteristics can be targeted in the analysis.

PBP based on task fMRI can distinguish participants based on the level of motor cortex activation, making it easier to group people based on their motor disorder's severity. This stratification allows an easy comparison between changes in brain activity and Motor function, as well other symptoms associated with Huntington's disease [15].

At its most basic level, PET imaging can divide people according to the amount of neuroinflammation in the brain or the density of dopamine receptors. This imaging technique allows researchers to evaluate treatment efficacy in relation to the identified pathophysiological subtypes.

MEG

MEG stratification by MEG depends on cerebral oscillatory patterns. The smooth perilesional motor network oscillations certainly will enable researchers to study subgroups who show early motor signs separately from those primarily with more severe motor changes.

Safety Monitoring

By using Neuroimaging, risks to the participants involved in experimental treatment are well observed over time, especially concerning neurotoxicity. Structural MRI: MRI scans, which are taken over time, give volumes of the brain and thus one can determine any accidental atrophy. This has made it easy to monitor any effect of neurodegeneration or any other side effect of these treatments in brain areas that may be affected periodically.

- *Diffusion MRI:* In this way, conducting dMRI over time permits assessing the white matter FA and MD because therapy side effects may decrease FA or increase MD unexpectedly depending on the efficacy of overnight new drugs or gene therapies [16].
- *fMRI:* As for the supervision, such therapy can be observed using fMRI, as it may reveal changes in the connectivity in certain areas of the brain, associated with off-target effects if the therapy interferes with networks connected to cognition or motor function.
- *MRS:* MRS records variability in the intensities of neurotransmitters including high levels of glutamate or low levels of GABA as a sign of possible neurotoxicity. A longitudinal MRS measurement minimizes the likelihood of participants suffering from metabolic disturbances resulting from therapies [17].

- *PET Imaging:* PET scans show neuroinflammation by means of identifying activated microglia. It is possible to predict and control worse behavioral reactions to new therapies with stepped up developments in neuroinflammation detection technology.
- *MEG:* MEG is applied in capturing functional disturbances of brain oscillations as caused by treatments. Alteration in oscillatory activity could also mean neurofunctional side effects which may be useful to change treatment strategies.

Neuroimaging as a Tool to Demonstrate Biodistribution, Target Engagement and Pharmacodynamics:

Structural MRI

Structural MRI Wi-Fi tracking changes in volumes, but mainly in structures, such as the striatum. These changes must be monitored to get an idea of the drug biodistribution in the course of time and differentiate structural modifications that could hint at target engagement and probable neuroprotection outcomes could be formed.

Diffusion MRI

dMRI estimates white matter properties employing other measures, such as fractional anisotropy values, for instance. White matter alterations may report drug effects on axonal functionality as well as on brain connectivity and thus indicate target engagement.

Functional MRI

fMRI captures the Brain's activity through blood-oxygen-level-dependent signals usually abbreviated as BOLD. Changes in network connectivity or activity, especially in motor circuits is useful in defining pharmacodynamic effects and functional activation of the regions of interest.

Magnetic Resonance Spectroscopy (MRS)

MRS provides biochemical information about the drug ongoing process in the brain as it measures brain metabolites including glutamate and GABA. Changes in these metabolites help to determine target engagement at the molecular level to support the assessment of pharmacodynamic responses.

Positron Emission Tomography (PET)

PET detects molecular alterations with tracer molecules, such as receptor availability and inflammation. PET can directly quantify target interaction and coverage in an experiment, making a pharmacodynamic evaluation of the treatment by estimating the receptor occupancy or inflammation.

Magnetoencephalography (MEG)

MEG acquires oscillatory neuronal signals on a beat-to-beat basis – alluding to changes in synchronized neural function. They enable the assessment of functional modification of the circuit's connectivity for the purposes of drug outcomes, making for real-time identification of target interactions and pharmacodynamics within the neural system

Neuroimaging as Tool to Provide Evidence for Disease Modification

For most HD trials, neuroimaging is instrumental in confirming the existence of disease modification, basically offering the foundation that allows HTA study teams reliably to answer the question: do these interventions make a real difference in disease progression? This is particularly important for proving the applicability of putative interventions to alter the disease's course in HD patients. In a review paper format, each imaging modality's contributions could be systematically analyzed as follows:

Structural MRI

Structural MRI can generate longitudinal data on the development alterations in gray and white matter volumes, at specific locations that are vulnerable to HD: the striatum and cortex. The use of structural MRI makes it easy to measure disease modification in terms of brain atrophy over time. For

example, processes or interventions which demonstrated the ability to reduce atrophy rates would be disease modified based on serial MRI evaluations.

Diffusion MRI (dMRI)

Preprocessing and post-processing allow the following features of white matter characterization by diffusion MRI: fractional anisotropy (FA) mean diffusivity (MD). It is in HD that these metrics tend to show abnormality in the cortico-striatal connections. An intervention approach that will keep or enhance these FA values will suggest structural salvage and disease amelioration, characteristics of white matter.

Functional MRI (fMRI)

fMRI identifies alterations in communication within and between neural networks which are both implicated in HD, such as the motor and the default mode networks. Maintenance or the reversal of connectivity deterioration through fMRI may be indicative of therapeutic induced functional plasticity alteration at the level of connectivity in a network, and thus disease modification.

The Second is Magnetic Resonance Spectroscopy (MRS)

MRS measures brain metabolites, and the values of such, as glutamate and GABA are frequently altered in HD. Observations of alteration in these metabolic coefficients over time indicate that organs are biochemically stabilizing or improving with therapy. Normalization of neurotransmitter concentrations would prove the pharmacological mechanisms for decelerated disease progression and potential metabolic contributors to disease modification.

PET is Short for Positron Emission Tomography

Most importantly, PET imaging provides the capability to assess molecular changes directly, such as dopamine receptors and inflammation. In this manner, PET markers can indicate the neuroprotection where a therapy change has pulled back neuro inflammation or slowed down receptor loss. These pharmacodynamic changes are also flagged by PET to play a crucial role in identifying disease modification at the molecular level.

Magnetoencephalography (MEG)

MEG records time-varying neural oscillations and coupling, which are particularly impaired in HD. The variations in oscillatory function by therapy in MEG can be used as a functional marker to show that disease related alterations in neural circuitry are being reversed

Neuroimaging as a Tool to Understand Brain Re-Organization Following Therapy

Given the nature of HD and studies on the disease, neuroimaging has proved to be useful for tracking the way the brain rewires and compensates after treatments. Perhaps if more review papers were to be published on this topic, one could get an outline of various imaging techniques that could be used and the role they play in understanding rehabilitation, neuroplasticity and functional reorganization. Here is how each neuroimaging modality contributes to understanding these processes:

Structural MRI

Structural MRI enables tracking of a progressive increase in or decrease in brain volume, including the areas that may be of special interest, such as the striatum, cortex, or white matter tracts. If after therapy, structural MRI shows further enhancement of these areas or at least their preservation it can point to specific neuroprotective or even to the fact of regeneration of damaged tissue. Such changes might indicate that therapy has helped brain grow or structures important for exceptionally functioning to be preserved as indication of brain structural reorganization.

Diffusion MRI (dMRI)

Diffusion MRI gives information on white matter and connection courses by obtaining values, such as FA and MD. Preservation or enhancement of FA or stable MD values on the white matter tracts after

therapy indicates that neural connections are being saved or repaired, according to the study. This form of reorganization may signal for improved interaction between neural networks to facilitate compensatory mechanisms to counter HD progression.

Functional MRI (fMRI)

fMRI is crucial to understand the dynamic nature of neural activity following the therapeutic interventions done in the present study in the motor and cognitive networks that are implicated in HD. The connectivity within these networks is found to increase after therapy meaning the brain rewires itself when there is damage. These and the network plasticity significantly describe functional reorganization of a network usually associated with better motor or cognitive function.

MRS is an abbreviation for Magnetic Resonance Spectroscopy. MRS measures alterations in brain metabolite concentrations, for example, glutamate and GABA which are known to be perverse in the HD. After therapy, changes in the metabolite contrast in areas involved in motor or cognitive tasks may point to other biochemical reorganization in response to recovery or equilibrium in neurotransmitter homeostasis. These molecular changes may prompt that the brain is responding to the therapeutic intervention in as much as functional compensation. Positron Emission Tomography is commonly referred to as PET. PET detection enables monitoring of molecular probes of brain activity, including dopamine receptors and neuroinflammatory changes that occur in neurodegenerative diseases. Decreases in neuroinflammation after therapy, or the mere recovery of receptor density, could reflect reorganization of brain tissue supporting the remaining functions. For example, a therapy that removes inflammation may promote cultivating new neural connections that would improve compensatory capacity and reorganization.

Magnetoencephalography (MEG)

MEG records acute neural oscillations and their connectivity, allowing for understanding of the temporal changes of brain connectivity. After therapy, an enhancement of inter-cortex phase synchronization or phase locking and frequency characteristics of the oscillatory activity within the dysfunctional networks implies positive remodeling of connectivity. Such reorganization at the oscillatory level may be suggestive of the upregulation of neuroplasticity where the brain is quite engaged in supporting motor and cognitive recovery.

CONCLUSIONS

Neuroimaging plays a critical role in improving clinical trials in Huntington disease (HD) as a means of participant inclusion and exclusion, safety assessment, and identification of the impact of intervention on disease advancement. determination of acceptable imaging techniques and measurement standards, quality controls, and the selection of correct analyzers. There are a number of specific and well-developed study procedures required for generating accurate data, upon which disease change is judged; a large part of which depends upon superior site configurations.

Technical advance and innovation here illustrated by the development of a mutant huntingtin (mHTT) PET ligand allows the direct visualization of the pathogenic protein in Huntington disease thereby increasing the accuracy of determining clinical trial efficacy. Advancements including the PET-MRI hybrid system, prevalence of programs centralizing imaging approaches, and time optimization in acquisition is expected to greatly improve data quality and patients' involvement. With these technologies emerging, they will continue to support the core application of neuroimaging in trials for HD, moving us closer to meaningful disease modifying drugs for HD.

REFERENCES

1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Huntington's Disease Collaborative Research Group. Cell. 1993;72(6):971–83.

2. Ghosh R, Tabrizi SJ. Clinical features of Huntington's disease. Adv Exp Med Biol. 2018;1049:1–28.
3. Tabrizi SJ, Estevez-Fraga C, van Roon-Mom WMC, Flower MD, Scahill RI, Wild EJ, et al. Potential disease-modifying therapies for Huntington's disease: Lessons learned and future opportunities. Lancet Neurol. 2022;21(7):645–58.
4. Poudel GR, Stout JC, Domínguez DJF, Churchyard AJ. Functional changes in the cortico-striatal network in early Huntington's disease: An fMRI study. Brain Imaging Behav. 2014;8(4):540–52.
5. Kaplan S, Itzkovitz S, Shapiro E. A universal mechanism ties genotype to phenotype in trinucleotide diseases. PLoS Comput Biol. 2007;3(11):e235.
6. Schwarz AJ. The use, standardization, and interpretation of brain imaging data in clinical trials of neurodegenerative disorders. Neurotherapeutics. 2021;18(2):686–708.
7. McGowan JC. Basic principles of magnetic resonance imaging. Neuroimaging Clin N Am. 2008;18(4):623–36.
8. Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, et al. Potential disease-modifying therapies for Huntington's disease: Progress and challenges. Lancet Neurol. 2019;18(11):1015–26.
9. Paulsen JS, Long JD, Ross CA, PREDICT-HD Investigators. Brain atrophy in early Huntington's disease: Evidence from PREDICT-HD study. J Neurol Neurosurg Psychiatry. 2014;85(12):1231–9.
10. Estevez-Fraga C, Scahill RI, Tabrizi SJ. Diffusion MRI metrics in Huntington's disease: A review of applications and limitations. J Neuroimaging. 2020;30(4):461–71.
11. Sturrock A, Leavitt BR. The potential of PET imaging in Huntington's disease clinical trials. J Huntingtons Dis. 2015;4(3):239–51.
12. Cozzi L, Zago S, Tabrizi SJ. Insights from magnetic resonance spectroscopy in Huntington's disease. Neurobiol Dis. 2020;144:105018.
13. Scahill RI, Zeun P, Osborne-Crowley K, Johnson EB, Gregory S, Parker C, et al. Biological and clinical impact of genetic variability in Huntington's disease: An MRI-based study. Nat Commun. 2020;11(1):1–13.
14. Gregory S, Crawford H, Tabrizi SJ. Multi-modal neuroimaging in Huntington's disease: A future perspective. J Neurol. 2015;262(6):1463–74.
15. Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt BR, Owen G, et al. Potential clinical and neuroimaging biomarkers in Huntington's disease: A prospective study. Nat Rev Neurol. 2019;15(4):235–47.
16. De Santis S, Smith M, Bells S, Assaf Y, Jones DK. Why diffusion tensor MRI does well only some of the time: Variance and covariance of white matter tissue restructure attributes in the living human brain. Neuroimage. 2014;89:35–47.
17. Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay CE, et al. Tract-based spatial statistics: Voxelwise analysis of multi-subject diffusion data. Neuroimage. 2006;31(4):1487–505.

